Logo image
Failure of combined chloroquine and High-Dose primaquine therapy for plasmodium vivax malaria acquired in Guyana, South America
Journal article   Open access   Peer reviewed

Failure of combined chloroquine and High-Dose primaquine therapy for plasmodium vivax malaria acquired in Guyana, South America

E.J. Phillips, J.S. Keystone and K.C. Kain
Clinical Infectious Diseases, Vol.23(5), pp.1171-1173
1996
pdf
failure_of_combined_chloroquine.pdfDownloadView
Published (Version of Record) Open Access
url
Link to Published Version *Subscription may be requiredView

Abstract

The presence of chloroquine-resistant Plasmodium vivax malaria in the New World has been suspected but not confirmed. We report the cases of three patients who acquired vivax malaria in Guyana, South America, and for whom standard chloroquine therapy (25 mg/kg) failed despite therapeutic blood levels. The optimal treatment of chloroquine-resistant P. vivax malaria is unknown, but recent studies suggest that a combination of chloroquine (25 mg/kg) and high-dose primaquine (2.5 mg/kg over 48 hours) is effective therapy. Two of our patients had recurrences of P. vivax malaria 6–8 weeks after receiving directly observed therapy with this combination. These cases confirm the presence of chloroquine-resistant P. vivax in Guyana and emphasize the need for better treatment regimens for chloroquine-resistant and primaquine-resistant P. vivax malaria.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

443 File views/ downloads
73 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics
1 Clinical & Life Sciences
1.217 Parasitology - Malaria, Toxoplasmosis & Coccidiosis
1.217.59 Malaria
Web Of Science research areas
Immunology
Infectious Diseases
Microbiology
ESI research areas
Immunology
Logo image